Provided by Tiger Fintech (Singapore) Pte. Ltd.

Quoin Pharmaceuticals

6.47
-0.0999-1.52%
Volume:5.49K
Turnover:36.15K
Market Cap:3.81M
PE:-0.10
High:7.09
Open:6.67
Low:6.41
Close:6.57
Loading ...

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study

GlobeNewswire
·
27 Feb

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

GlobeNewswire
·
25 Feb

Quoin Pharmaceuticals launches ‘NETHERTON NOW’ campaign

TIPRANKS
·
04 Feb

Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

GlobeNewswire
·
04 Feb

Insider Buyers At Quoin Pharmaceuticals Likely Disappointed With 13% Slide

Simply Wall St.
·
02 Feb

Quoin Pharmaceuticals: Buy Rating Affirmed Amidst Potential First-Mover Advantage in Netherton Syndrome Treatment

TIPRANKS
·
25 Jan

Skinvisible Advances with Quoin Pharmaceuticals’ FDA Clearance

TIPRANKS
·
24 Jan

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

GlobeNewswire
·
23 Jan

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

ACCESS Newswire
·
23 Jan

Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study

GlobeNewswire
·
14 Jan

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials

GlobeNewswire
·
08 Jan

Buy Rating Reaffirmed for Quoin Pharmaceuticals Amid Promising QRX003 Developments and Market Potential

TIPRANKS
·
08 Jan

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

GlobeNewswire
·
06 Jan

Quoin Pharmaceuticals Prices $6.8 Million Equity Offering -- Shares Fall

MT Newswires Live
·
21 Dec 2024

Quoin Pharmaceuticals prices 15.1M ADSs at 45c in public offering

TIPRANKS
·
20 Dec 2024

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

GlobeNewswire
·
20 Dec 2024

Quoin Pharmaceuticals announces FDA clearance to initiate QRX003 study

TIPRANKS
·
19 Dec 2024

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

GlobeNewswire
·
18 Dec 2024

Quoin Pharmaceuticals files to sell 19.23M ordinary shares

TIPRANKS
·
12 Dec 2024

Quoin Pharmaceuticals Annual Meeting Approves Key Amendments

TIPRANKS
·
11 Dec 2024